- Home
- TLSI vs ELTX Comparison
TLSI vs ELTX Comparison
Compare TLSI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- ELTX
- Stock Information
- Founded
- TLSI 2010
- ELTX 2011
- Country
- TLSI United States
- ELTX United States
- Employees
- TLSI N/A
- ELTX N/A
- Industry
- TLSI Medical Specialities
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- ELTX Health Care
- Exchange
- TLSI Nasdaq
- ELTX Nasdaq
- Market Cap
- TLSI 150.0M
- ELTX 121.7M
- IPO Year
- TLSI N/A
- ELTX N/A
- Fundamental
- Price
- TLSI $3.94
- ELTX $10.00
- Analyst Decision
- TLSI Strong Buy
- ELTX Strong Buy
- Analyst Count
- TLSI 5
- ELTX 2
- Target Price
- TLSI $10.90
- ELTX $11.00
- AVG Volume (30 Days)
- TLSI 73.5K
- ELTX 52.5K
- Earning Date
- TLSI 08-12-2025
- ELTX 08-07-2025
- Dividend Yield
- TLSI N/A
- ELTX N/A
- EPS Growth
- TLSI N/A
- ELTX N/A
- EPS
- TLSI N/A
- ELTX N/A
- Revenue
- TLSI $35,990,000.00
- ELTX N/A
- Revenue This Year
- TLSI $55.39
- ELTX N/A
- Revenue Next Year
- TLSI $54.89
- ELTX N/A
- P/E Ratio
- TLSI N/A
- ELTX N/A
- Revenue Growth
- TLSI 45.50
- ELTX N/A
- 52 Week Low
- TLSI $3.42
- ELTX $3.70
- 52 Week High
- TLSI $6.04
- ELTX $10.75
- Technical
- Relative Strength Index (RSI)
- TLSI 39.84
- ELTX 58.06
- Support Level
- TLSI $3.42
- ELTX $8.51
- Resistance Level
- TLSI $4.00
- ELTX $9.99
- Average True Range (ATR)
- TLSI 0.36
- ELTX 0.68
- MACD
- TLSI -0.01
- ELTX -0.08
- Stochastic Oscillator
- TLSI 34.75
- ELTX 55.36
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.